PET Imaging May Not Improve Diagnostic Accuracy in Early Head and Neck Cancer
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




PET Imaging May Not Improve Diagnostic Accuracy in Early Head and Neck Cancer

NEW YORK -- May 14, 2008 -- Positron emission tomography with a radioactive tracer (18F-FDG PET) may not improve the detection of small metastases in patients with head and neck cancer who have no clinical evidence of disease in neighbouring lymph nodes, suggest results published in the May 13 issue of the Journal of the National Cancer Institute.

To systematically examine the value of FDG PET for diagnosing clinically node-negative patients, John P.A. Ioannidis, MD, University of Ioannina School of Medicine, Ioannina, Greece, and colleagues performed a meta-analysis of 32 previously published studies that tested FDG PET in patients with head and neck cancer with 1 or fewer nodal metastases.

FDG PET failed to identify 50% of the occult lesions in clinically node-negative patients and incorrectly identified normal tissue as being cancerous 13% of the time.

When the researchers compared the sensitivity and specificity of FDG PET with magnetic resonance imaging and commuted tomography, they found that there was a trend for a small improvement in detection with FDG PET, but the differences were not statistically significant. The false-positive rate was similar for all 3 imaging techniques.

"Thus, there is little evidence to support the routine use of 18F-FDG PET to evaluate possible lymph node metastasis among patients with [head and neck squamous cell cancer] and a clinically [node-] negative neck," the authors said.

SOURCE: Journal of the National Cancer Institute

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities